Effect of the new matrix metalloproteinase inhibitor RO-28-2653 on mitochondrial function.

Matrix metalloproteinases (MMPs) have recently become interesting as potential anticancer drugs. RO-28-2653 is a promising compound because of its antimetastatic and antiangiogenic activities. Due to the structural similarity of RO-28-2653 to mitochondriotoxic agents, speculation has arisen that this substance might impair mitochondrial function. We, therefore, investigated the effects of RO-28-2653 on mitochondrial enzymes and on the functional properties of isolated mitochondria and skinned muscle fibers from rat hearts. Results were compared to the action of amytal and 2,4-dinitrophenol (2,4-DNP), both of which are well documented mitochondriotoxic compounds. In contrast to 2,4-DNP, RO-28-2653 did not uncouple oxidative phosphorylation, although higher concentrations of the compound did impair mitochondrial function. Using malate/pyruvate as substrate, 50 microM of RO-28-2653 inhibited mitochondrial respiration in isolated mitochondria and skinned fibers by 23 and 11%, respectively while 2mM of amytal elicited almost complete inhibition of the mitochondrial respiration. RO-28-2653 (50 micro) inhibited succinate-dependent respiration in both systems by 43 and 24%, respectively while 2mM of amytal caused 41 and 23% inhibition, respectively. There was no change in the ADP/O ratios. RO-28-2653 (50 microM) did not significantly alter the activity of the respiratory chain complexes or succinate dehydrogenase, although citrate synthase (CS) was inhibited by upto 71%. This inhibition was non-competitive at a K(i) of 25+/-5 microM. Inhibitory effects in the presence of hydrophobic substances, such as BSA and Triton X-100, were significantly lower in both test systems. In conclusion, high concentrations of RO-28-2653 impair mitochondrial function, although compared to amytal and 2,4-DNP, this is rather low. The resultant impairment is less pronounced in the more complex skinned muscle fiber system, and is dependent on hydrophobic interactions.

[1]  R. Braun,et al.  Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. , 1988, Analytical biochemistry.

[2]  High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders , 1997 .

[3]  H. Shimada,et al.  Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. , 1998, Cancer research.

[4]  F. Gabreëls,et al.  A mitochondrial encephalomyopathy: the first case with an established defect at the level of coenzyme Q , 1986, European Journal of Pediatrics.

[5]  A. Tzagoloff,et al.  [45] Cytochrome oxidase from beef heart mitochondria , 1967 .

[6]  Y. Hatefi.  Flavoproteins of the electron transport system and the site of action of amytal, rotenone, and piericidin A. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[7]  I. Stamenkovic.  Matrix metalloproteinases in tumor invasion and metastasis. , 2000, Seminars in cancer biology.

[8]  M. Ortner,et al.  A respirometer for investigating oxidative cell metabolism: toward optimization of respiratory studies. , 1994, Analytical biochemistry.

[9]  I. Talbot,et al.  Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. , 1996, Cancer research.

[10]  B CHANCE,et al.  The respiratory chain and oxidative phosphorylation. , 1956, Advances in enzymology and related subjects of biochemistry.

[11]  S. Krähenbühl,et al.  Development and evaluation of a spectrophotometric assay for complex III in isolated mitochondria, tissues and fibroblasts from rats and humans. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[12]  M. Schlame,et al.  Dynamic compartmentation of adenine nucleotides in the mitochondrial intermembrane space of rat-heart mitochondria. , 1987, Biochimica et biophysica acta.

[13]  L. Matrisian,et al.  Matrix metalloproteinases: multifunctional contributors to tumor progression. , 2000, Molecular medicine today.

[14]  H. Tisdale.  [39] Preparation and properties of succinic—cytochrome c reductase (complex II–III) , 1967 .

[15]  G. Zbinden,et al.  Effect of antidepressant and neuroleptic drugs on respiratory function of rat heart mitochondria. , 1979, Biochemical pharmacology.

[16]  R. Bohnensack,et al.  Control of mitochondrial respiration. The contribution of the adenine nucleotide translocator depends on the ATP- and ADP-consuming enzymes. , 1983, Biochimica et biophysica acta.

[17]  V. Skulachev.  Uncoupling: new approaches to an old problem of bioenergetics. , 1998, Biochimica et biophysica acta.

[18]  H. Verspaget,et al.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. , 1996, British Journal of Cancer.

[19]  R. Béliveau,et al.  Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. , 1999, Canadian journal of physiology and pharmacology.

[20]  W. Kunz,et al.  Permeabilized cell and skinned fiber techniques in studies of mitochondrial function in vivo , 1998 .

[21]  R. Giavazzi,et al.  MMP Inhibitors: Experimental and Clinical Studies , 1999, The International journal of biological markers.

[22]  P. Kaheinen,et al.  Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. , 1997, European journal of pharmacology.

[23]  G I Murray,et al.  Matrix metalloproteinases in tumour invasion and metastasis , 1999, The Journal of pathology.

[24]  J. Chappell.  The effects of 2,4-dinitrophenol on mitochondrial oxidations. , 1964, The Biochemical journal.

[25]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase‐2 immunoreactive protein , 1998, Cancer.

[26]  M. Michaelides,et al.  Recent advances in matrix metalloproteinase inhibitors research. , 1999, Current pharmaceutical design.

[27]  P. Garland,et al.  [2] Citrate synthase from rat liver: [EC 4.1.3.7 Citrate oxaloacetage-lyase (CoA-acetylating)] , 1969 .

[28]  O. Arrigoni,et al.  Limitations of the Phenazine Methosulphate Assay for Succinic and Related Dehydrogenases , 1962, Nature.

[29]  C. Neuhoff,et al.  Function of the mitochondrial outer membrane as a diffusion barrier in health and diseases. , 2000, Biochemical Society transactions.

[30]  A. H. Drummond,et al.  Recent advances in matrix metalloproteinase inhibitor research , 1996 .